|
SE9301916D0
(sv)
|
1993-06-03 |
1993-06-03 |
Ab Astra |
New peptides derivatives
|
|
IL112795A
(en)
|
1994-03-04 |
2001-01-28 |
Astrazeneca Ab |
Peptide derivatives as antithrombic agents their preparation and pharmaceutical compositions containing them
|
|
AU742178B2
(en)
|
1998-05-26 |
2001-12-20 |
Merck & Co., Inc. |
Imidazopyridine thrombin inhibitors
|
|
AU3192500A
(en)
|
1999-03-16 |
2000-10-04 |
C & C Research Laboratories |
Substituted proline derivatives and medicinal compositions containing the same
|
|
US6653316B1
(en)
|
1999-05-19 |
2003-11-25 |
Pharmacia Corporation |
Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
|
|
US7015230B1
(en)
|
1999-05-19 |
2006-03-21 |
Pharmacia Corporation |
Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
|
|
CZ20014115A3
(cs)
|
1999-05-19 |
2002-05-15 |
Pharmacia Corporation |
Substituované polycyklické aryl a heteroaryl pyrazinony vhodné pro selektivní inhibici koagulační kaskády
|
|
AU2002230836A1
(en)
|
2000-12-18 |
2002-07-01 |
Merck & Co., Inc. |
Benzylamine derivatives and their use as thrombin inhibitors
|
|
MXPA04003167A
(es)
|
2001-10-03 |
2004-07-08 |
Pharmacia Corp |
Compuestos heterociclicos insaturados de 6 miembros utiles para la inhibicion selectiva de la cascada de coagulacion.
|
|
US20140056873A1
(en)
|
2004-06-10 |
2014-02-27 |
University Of Leicester |
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
|
|
US7919094B2
(en)
|
2004-06-10 |
2011-04-05 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
US8840893B2
(en)
|
2004-06-10 |
2014-09-23 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
KR20080002832A
(ko)
|
2005-03-16 |
2008-01-04 |
얀센 파마슈티카 엔.브이. |
보체 매개성 질병 및 이상을 치료하기 위한 신규한 티오펜설폭시민
|
|
RS51644B
(sr)
|
2007-01-10 |
2011-10-31 |
Irm Llc. |
Jedinjenja i preparati kao inhibitori kanal aktivirajuće proteaze
|
|
DK2488203T3
(en)
|
2009-10-16 |
2017-03-13 |
Omeros Corp |
METHODS OF TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITION OF MASP-2 DEPENDENT COMPLEMENT ACTIVATION
|
|
US9644035B2
(en)
|
2011-04-08 |
2017-05-09 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
BR112013025917A2
(pt)
|
2011-04-08 |
2016-12-20 |
Omeros Corp |
uso de um anticorpo masp-2 ou fragmento do mesmo que inibe ativação de complemento dependente de masp-2
|
|
HUE049154T2
(hu)
|
2011-05-04 |
2020-09-28 |
Omeros Corp |
Készítmények a MASP-2-függõ komplement-aktiválás gátlására
|
|
BR112014031522A2
(pt)
|
2012-06-18 |
2017-08-01 |
Omeros Corp |
métodos para inibir a ativação de complemento dependente de masp-3, para inibir a ativação de complemento dependente de masp-2 e para fabricar um medicamento
|
|
AR091490A1
(es)
|
2012-06-19 |
2015-02-11 |
Bristol Myers Squibb Co |
Antagonistas de iap
|
|
EP2922535B1
(en)
|
2012-11-20 |
2021-11-10 |
Merck Sharp & Dohme Corp. |
Thrombin inhibitors
|
|
JP2016539919A
(ja)
|
2013-10-17 |
2016-12-22 |
オメロス コーポレーション |
Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法
|
|
AU2016354117B2
(en)
|
2015-11-09 |
2019-11-28 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
KR102528260B1
(ko)
|
2016-01-05 |
2023-05-04 |
유니버시티 오브 레스터 |
필요로 하는 대상체에서 섬유증의 억제 방법
|
|
US20170253667A1
(en)
|
2016-01-05 |
2017-09-07 |
University Of Leicester |
Methods for inhibiting fibrosis in a subject in need thereof
|
|
MX2018011648A
(es)
|
2016-03-31 |
2019-01-30 |
Omeros Corp |
Metodos para la inhibicion de fibrosis en un sujeto en necesidad del mismo.
|
|
JOP20170170B1
(ar)
|
2016-08-31 |
2022-09-15 |
Omeros Corp |
صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
|
|
US20180105604A1
(en)
|
2016-10-13 |
2018-04-19 |
University Of Leicester |
Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
|
|
TWI881481B
(zh)
|
2017-08-15 |
2025-04-21 |
美商歐米諾斯公司 |
用於治療和／或預防與造血幹細胞移植有關的移植物抗宿主病和／或瀰漫性肺泡出血和／或靜脈閉塞性病的方法
|
|
PE20200924A1
(es)
|
2017-09-13 |
2020-09-14 |
Amgen Inc |
Compuestos de bisamida sustituida que activan el sarcomero cardiaco
|
|
GB201805174D0
(en)
*
|
2018-03-29 |
2018-05-16 |
Univ Leeds Innovations Ltd |
Compounds
|
|
GB201807014D0
(en)
|
2018-04-30 |
2018-06-13 |
Univ Leeds Innovations Ltd |
Factor xlla inhibitors
|
|
IL311042B1
(en)
*
|
2018-05-29 |
2026-04-01 |
Omeros Corp |
MASP-2 inhibitors and methods of use
|
|
EP4069676A1
(en)
|
2019-12-04 |
2022-10-12 |
Omeros Corporation |
Masp-2 inhibitors and methods of use
|
|
BR112022010895A2
(pt)
|
2019-12-04 |
2022-09-06 |
Omeros Corp |
Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan
|
|
IL293588B1
(en)
|
2019-12-04 |
2026-04-01 |
Omeros Corp |
3-Amino-1-methylpyrazin-2(H1)-one derivatives as MASP-2 inhibitors, compositions containing them and uses thereof
|